Our data indicate that class I HDAC inhibitors may directly promote brown fat thermogenesis, which may contribute to the beneficial effect of HDACis in obesity and its associated disorders, and that pharmacological inhibition of class I HDACs may serve as a promising therapeutic target for the prevention and treatment of obesity. Here, HDAC9 is linked to Obesity.